Hereditary periodic fever and reactive amyloidosis

Clinical and Experimental Medicine

Volumn 5, Issue 3, 2005, Pages 87-98

  Van Der Hilst, J C H ^a   Simon, A ^a   Drenth, J P H ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Amyloidosis; CAPS; FMF; HIDS; Periodic fever; SAA; TRAPS

Indexed keywords

AMYLOID A PROTEIN; AZATHIOPRINE; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOKINE RECEPTOR ANTAGONIST; ETANERCEPT; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SIMVASTATIN; THALIDOMIDE; TUMOR NECROSIS FACTOR RECEPTOR;

AMYLOIDOSIS; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DNA POLYMORPHISM; ETHNOLOGY; FAMILIAL MEDITERRANEAN FEVER; FEVER; GRAFT REJECTION; HEREDITARY PERIODIC FEVER SYNDROME; HUMAN; HYPERIMMUNOGLOBULINEMIA; INFLAMMATION; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEGRADATION; RECURRENT DISEASE; REVIEW; RISK; SIDE EFFECT; TREATMENT FAILURE;

AMYLOIDOSIS, FAMILIAL; CARRIER PROTEINS; FAMILIAL MEDITERRANEAN FEVER; HUMANS; HYPERGAMMAGLOBULINEMIA; IMMUNOGLOBULIN D; PROGNOSIS; RECEPTORS, TUMOR NECROSIS FACTOR; SERUM AMYLOID A PROTEIN;

EID: 27744602338     PISSN: 15918890     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10238-005-0071-6     Document Type: Review

References (167)

1. Drenth JPH, van der Meer JWM (2001) Hereditary periodic fever. N Engl J Med 345:1748-1757
2. Grateau G, Jeru I, Rouaghe S, Cazeneuve C, Ravet N, Duquesnoy P et al (2005) Amyloidosis and auto-inflammatory syndromes. Curr Drug Targets Inflamm Allergy 4:57-65
3. Falk RH, Comenzo RL, Skinner M (1997) The systemic amyloidoses. N Engl J Med 337:898-909
4. Merlini G, Bellotti V (2003) Molecular mechanisms of amyloidosis. N Engl J Med 349:583-596
5. Westermark P, Benson MD, Buxbaum JN, Cohen AS, Frangione B, Ikeda S et al (2002) Amyloid fibril protein nomenclature - 2002. Amyloid 9:197-200
6. Hoffman JS, Benditt EP (1982) Changes in high density lipoprotein content following endotoxin administration in the mouse. Formation of serum amyloid protein-rich subtractions. J Biol Chem 257:10510-10517
7. Marhaug G (1983) Three assays for the characterization and quantitation of human serum amyloid A. Scand J Immunol 18:329-338
8. Benson MD, Scheinberg MA, Shirahama T, Cathcart ES, Skinner M (1977) Kinetics of serum amyloid protein A in casein-induced murine amyloidosis. J Clin Invest 59:412-417
9. Uhlar CM, Burgess CJ, Sharp PM, Whitehead AS (1994) Evolution of the serum amyloid A (SAA) protein superfamily. Genomics 19:228-235
10. Xu L, Badolato R, Murphy WJ, Longo DL, Anver M, Hale S et al (1995) A novel biologic function of serum amyloid A. Induction of T lymphocyte migration and adhesion. J Immunol 155:1184-1190
11. Badolato R, Johnston JA, Wang JM, McVicar D, Xu LL, Oppenheim JJ et al (1995) Serum amyloid A induces calcium mobilization and chemotaxis of human monocytes by activating a pertussis toxin-sensitive signaling pathway. J Immunol 155:4004-4010
12. Hari-Dass R, Shah C, Meyer DJ, Raynes JG (2005) Serum amyloid A protein binds to outer membrane protein A of Gram-negative bacteria. J Biol Chem 280:18562-18567
13. Banka CL, Yuan T, de Beer MC, Kindy M, Curtiss LK, de Beer FC (1995) Serum amyloid A (SAA): influence on HDL-mediated cellular cholesterol efflux. J Lipid Res 36:1058-1065
14. Kisilevsky R (1991) Serum amyloid A (SAA), a protein without a function: some suggestions with reference to cholesterol metabolism. Med Hypotheses 35:337-341
15. Liang JS, Sipe JD (1995) Recombinant human serum amyloid A (apoSAAp) binds cholesterol and modulates cholesterol flux. J Lipid Res 36:37-46
16. Tape C, Tan R, Nesheim M, Kisilevsky R (1988) Direct evidence for circulating apoSAA as the precursor of tissue AA amyloid deposits. Scand J Immunol 28:317-324
17. Husebekk A, Skogen B, Husby G, Marhaug G (1985) Transformation of amyloid precursor SAA to protein AA and incorporation in amyloid fibrils in vivo. Scand J Immunol 21:283-287
18. Sletten K, Husby G (1974) The complete amino-acid sequence of non-immunoglobulin amyloid fibril protein AS in rheumatoid arthritis. Eur J Biochem 41:117-125
19. Prelli F, Pras M, Frangione B (1987) Degradation and deposition of amyloid AA fibrils are tissue specific. Biochemistry 26:8251-8256
20. Rocken C, Menard R, Buhling F, Vockler S, Raynes J, Stix B et al (2005) Proteolysis of serum amyloid A and AA amyloid proteins by cysteine proteases: cathepsin B generates AA amyloid proteins and cathepsin L may prevent their formation. Ann Rheum Dis 64:808-815
21. Skogen B, Thorsteinsson L, Natvig JB (1980) Degradation of protein SAA to an AA-like fragment by enzymes of monocytic origin. Scand J Immunol 11:533-540
22. Shirahama T, Cohen AS (1975) Intralysosomal formation of amyloid fibrils. Am J Pathol 81:101-116
23. Kluve-Beckerman B, Manaloor J, Liepnieks JJ (2001) Binding, trafficking and accumulation of serum amyloid A in peritoneal macrophages. Scand J Immunol 53:393-400
24. Takahashi M, Yokota T, Kawano H, Gondo T, Ishihara T, Uchino F (1989) Ultrastructural evidence for intracellular formation of amyloid fibrils in macrophages. Virchows Arch A Pathol Anat Histopathol 415:411-419
25. Yamada T, Kluve-Beckerman B, Liepnieks JJ, Benson MD (1995) In vitro degradation of serum amyloid A by cathepsin D and other acid proteases: possible protection against amyloid fibril formation. Scand J Immunol 41:570-574
26. Yamada T, Liepnieks JJ, Kluve-Beckerman B, Benson MD (1995) Cathepsin B generates the most common form of amyloid A (76 residues) as a degradation product from serum amyloid A. Scand J Immunol 41:94-97
27. Rocken C, Stix B, Bromme D, Ansorge S, Roessner A, Buhling F (2001) A putative role for cathepsin K in degradation of AA and AL amyloidosis. Am J Pathol 158:1029-1038
28. Lavie G, Zucker-Franklin D, Franklin EC (1980) Elastase-type proteases on the surface of human blood monocytes: possible role in amyloid formation. J Immunol 125:175-180
29. Tennent GA, Lovat LB, Pepys MB (1995) Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proc Natl Acad Sci USA 92:4299-4303
30. Gellermann GP, Appel TR, Tannert A, Radestock A, Hortschansky P, Schroeckh V et al (2005) Raft lipids as common components of human extracellular amyloid fibrils. Proc Natl Acad Sci U.S.A. 102:6297-6302
31. Li JP, Galvis ML, Gong F, Zhang X, Zcharia E, Metzger S et al (2005) In vivo fragmentation of heparan sulfate by heparanase overexpression renders mice resistant to amyloid protein A amyloidosis. Proc Natl Acad Sci U.S.A. 102:6473-6477
32. Janssen S, van Rijswijk MH, Meijer S, Ruinen L, Van der Hem GK (1986) Systemic amyloidosis: a clinical survey of 144 cases. Neth J Med 29:376-385
33. Gertz MA, Kyle RA (1991) Secondary systemic amyloidosis: response and survival in 64 patients. Medicine (Baltimore) 70:246-256
34. Legge DA, Wollaeger EE, Carlson HC (1970) Intestinal pseudo-obstruction in systemic amyloidosis. Gut 11:764-767
35. Hamed G, Heffess CS, Shmookler BM, Wenig BM (1995) Amyloid goiter. A clinicopathologic study of 14 cases and review of the literature. Am J Clin Pathol 104:306-312
36. Mainenti PP, Cantalupo T, Nicotra S, Camera L, Imbriaco M, Di Vizio D et al (2004) Systemic amyloidosis: the CT sign of splenic hypoperfusion. Amyloid 11:281-282
37. Tuglular S, Yalcinkaya F, Paydas S, Oner A, Utas C, Bozfakioglu S et al (2002) A retrospective analysis for aetiology and clinical findings of 287 secondary amyloidosis cases in Turkey. Nephrol Dial Transplant 17:2003-2005
38. Dubrey SW, Cha K, Simms RW, Skinner M, Falk RH (1996) Electrocardiography and Doppler echocardiography in secondary (AA) amyloidosis. Am J Cardiol 77:313-315
39. Hazenberg BP, van Gameren II, Bijzet J, Jager PL, van Rijswijk MH (2004) Diagnostic and therapeutic approach of systemic amyloidosis. Neth J Med 62:121-128
40. Klemi PJ, Sorsa S, Happonen RP (1987) Fine-needle aspiration biopsy from subcutaneous fat. An easy way to diagnose secondary amyloidosis. Scand J Rheumatol 16:429-431
41. Libbey CA, Skinner M, Cohen AS (1983) Use of abdominal fat tissue aspirate in the diagnosis of systemic amyloidosis. Arch Intern Med 143:1549-1552
42. Duston MA, Skinner M, Meenan RF, Cohen AS (1989) Sensitivity, specificity, and predictive value of abdominal fat aspiration for the diagnosis of amyloidosis. Arthritis Rheum 32:82-85
43. Breedveld FC, Markusse HM, MacFarlane JD (1989) Subcutaneous fat biopsy in the diagnosis of amyloidosis secondary to chronic arthritis. Clin Exp Rheumatol 7:407-410
44. Paydas S (1999) Report on 59 patients with renal amyloidosis. Int Urol Nephrol 31:619-631
45. Kyle RA, Gertz MA (1995) Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 32:45-59
46. Sungur C, Sungur A, Ruacan S, Arik N, Yasavul U, Turgan C et al (1993) Diagnostic value of bone marrow biopsy in patients with renal disease secondary to familial Mediterranean fever. Kidney Int 44:834-836
47. Kyle RA, Bayrd ED (1975) Amyloidosis: review of 236 cases. Medicine (Baltimore) 54:271-299
48. Falck HM, Maury CP, Teppo AM, Wegelius O (1983) Correlation of persistently high serum amyloid A protein and C-reactive protein concentrations with rapid progression of secondary amyloidosis. Br Med J (Clin Res Ed) 286:1391-1393
49. Joss N, McLaughlin K, Simpson K, Boulton-Jones JM (2000) Presentation, survival and prognostic markers in AA amyloidosis. Q J Med 93:535-542
50. Tanaka F, Migita K, Honda S, Fukuda T, Mine M, Nakamura T et al (2003) Clinical outcome and survival of secondary (AA) amyloidosis. Clin Exp Rheumatol 21:343-346
51. Browning MJ, Banks RA, Tribe CR, Hollingworth P, Kingswood C, Mackenzie JC et al (1985) Ten years' experience of an amyloid clinic - a clinicopathological survey. Q J Med 54:213-227.
52. Merlini G (2004) Systemic amyloidosis: are we moving ahead? Neth J Med 62:104-105
53. Gillmore JD, Lovat LB, Persey MR, Pepys MB, Hawkins PN (2001) Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 358:24-29
54. Ben Chetrit E, Levy M (1998) Familial Mediterranean fever. Lancet 351:659-664
55. The French FMF Consortium (1997) A candidate gene for familial Mediterranean fever. Nat Genet 17:25-31
56. The International FMF Consortium (1997) Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell 90:797-807
57. Touitou I, Lesage S, McDermott M, Cuisset L, Hoffman H, Dode C et al (2004) Infevers: an evolving mutation database for auto-inflammatory syndromes. Hum Mutat 24:194-198
58. Centola M, Wood G, Frucht DM, Galon J, Aringer M, Farrell C et al (2000) The gene for familial Mediterranean fever. MEFV, is expressed in early leukocyte development and is regulated in response to inflammatory mediators. Blood 95:3223-3231
59. Ting JP, Davis BK (2005) CATERPILLER: a novel gene family important in immunity, cell death, and diseases. Annu Rev Immunol 23:387-414
60. Richards N, Schaner P, Diaz A, Stuckey J, Shelden E, Wadhwa A et al (2001) Interaction between pyrin and the apoptotic speck protein (ASC) modulates ASC-induced apoptosis. J Biol Chem 276:39320-39329
61. Stehlik C, Lee SH, Dorfleutner A, Stassinopoulos A, Sagara J, Reed JC (2003) Apoptosis-associated speck-like protein containing a caspase recruitment domain is a regulator of procaspase-1 activation. J Immunol 171:6154-6163
62. Sohar E, Gafni J, Pras M, Heller H (1967) Familial Mediterranean fever. A survey of 470 cases and review of the literature. Am J Med 43:227-253
63. Barakat MH, Karnik AM, Majeed HW, el Sobki NI, Fenech FF (1986) Familial Mediterranean fever (recurrent hereditary polyserositis) in Arabs - a study of 175 patients and review of the literature. Q J Med 60:837-847
64. Samuels J, Aksentijevich I, Torosyan Y, Centola M, Deng Z, Sood R et al (1998) Familial Mediterranean fever at the millennium. Clinical spectrum, ancient mutations, and a survey of 100 American referrals to the National Institutes of Health. Medicine (Baltimore) 77:268-297
65. Tunca M, Akar S, Onen F, Ozdogan H, Kasapcopur O, Yalcinkaya F et al (2005) Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine (Baltimore) 84:1-11
66. Korkmaz C, Ozdogan H, Kasapcopur O, Yazici H (2002) Acute phase response in familial Mediterranean fever. Ann Rheum Dis 61:79-81
67. Kees S, Langevitz P, Zemer D, Padeh S, Pras M, Livneh A (1997) Attacks of pericarditis as a manifestation of familial Mediterranean fever (FMF). Q J Med 90:643-647
68. Gafni J, Ravid M, Sohar E (1968) The role of amyloidosis in familial Mediterranean fever. A population study. Isr J Med Sci 4:995-999
69. Cefle A, Kamali S, Sayarlioglu M, Inanc M, Ocal L, Aral O et al (2004) A comparison of clinical findings of familial Mediterranean fever patients with and without amyloidosis. Rheumatol Int 25:442-446
70. Konstantopoulos K, Kanta A, Tzoulianos M, Dimou S, Sotsiou F, Politou M et al (2001) Familial Mediterranean fever phenotype II in Greece. Isr Med Assoc J 3:862-863
71. Kutlay S, Yilmaz E, Koytak ES, Tulunay OO, Keven K, Ozcan M et al (2001) A case of familial Mediterranean fever with amyloidosis as the first manifestation. Am J Kidney Dis 38:E34
72. Melikoglu M, Ozdogan H, Korkmaz C, Kasapcopur O, Arisoy N, Akkus S et al (2000) A survey of phenotype II in familial Mediterranean fever. Ann Rheum Dis 59:910-913
73. Pras M, Bronshpigel N, Zemer D, Gafni J (1982) Variable incidence of amyloidosis in familial Mediterranean fever among different ethnic groups. Johns Hopkins Med J 150:22-26
74. Mimouni A, Magal N, Stoffman N, Shohat T, Minasian A, Krasnov M et al (2000) Familial Mediterranean fever: effects of genotype and ethnicity on inflammatory attacks and amyloidosis. Pediatrics 105:E70
75. Ben Chetrit E, Backenroth R (2001) Amyloidosis induced, end stage renal disease in patients with familial Mediterranean fever is highly associated with point mutations in the MEFV gene. Ann Rheum Dis 60:146-149
76. Mansour I, Delague V, Cazeneuve C, Dode C, Chouery E, Pecheux C et al (2001) Familial Mediterranean fever in Lebanon: mutation spectrum, evidence for cases in Maronites, Greek orthodoxes, Greek catholics, Syriacs and Chiites and for an association between amyloidosis and M694V and M694I mutations. Eur J Hum Genet 9:51-55
77. Gershoni-Baruch R, Brik R, Zacks N, Shinawi M, Lidar M, Livneh A (2003) The contribution of genotypes at the MEFV and SAA1 loci to amyloidosis and disease severity in patients with familial Mediterranean fever. Arthritis Rheum 48:1149-1155
78. Langevitz P, Livneh A, Padeh S, Zaks N, Shinar Y, Zemer D et al (1999) Familial Mediterranean fever: new aspects and prospects at the end of the millenium. Isr Med Assoc J 1:31-36
79. Cazeneuve C, Ajrapetyan H, Papin S, Roudot-Thoraval F, Genevieve D, Mndjoyan E et al (2000) Identification of MEFV-independent modifying genetic factors for familial Mediterranean fever. Am J Hum Genet 67:1136-1143
80. Brik R, Shinawi M, Kepten I, Berant M, Gershoni-Baruch R (1999) Familial Mediterranean fever: clinical and genetic characterization in a mixed pediatric population of Jewish and Arab patients. Pediatrics 103:e70
81. Cazeneuve C, Sarkisian T, Pecheux C, Dervichian M, Nedelec B, Reinert P et al (1999) MEFV-gene analysis in Armenian patients with Familial Mediterranean fever: diagnostic value and unfavorable renal prognosis of the M694V homozygous genotype - genetic and therapeutic implications. Am J Hum Genet 65:88-97
82. Altiok O, Seguret F, Touitou I (2003) MEFV sequence variants and amyloidosis: still an enigmatic question. Hum Mutat 21:96-97
83. Akar E, Yalcinkaya F, Akar N (2001) Is the Ala138Gly alteration of MEFV gene important for amyloidosis? Hum Mutat 17:71
84. Yalcinkaya F, Cakar N, Misirlioglu M, Tumer N, Akar N, Tekin M et al (2000) Genotype-phenotype correlation in a large group of Turkish patients with familial Mediterranean fever: evidence for mutation-independent amyloidosis. Rheumatology (Oxford) 39:67-72
85. Atagunduz MP, Tuglular S, Kantarci G, Akoglu E, Direskeneli H (2004) Association of FMF-related (MEFV) point mutations with secondary and FMF amyloidosis. Nephron Clin Pract 96:c131-c135
86. Kone Paut I, Dubuc M, Sportouch J, Minodier P, Garnier JM, Touitou I (2000) Phenotype-genotype correlation in 91 patients with familial Mediterranean fever reveals a high frequency of cutaneomucous features. Rheumatology (Oxford) 39:1275-1279
87. Yilmaz E, Balci B, Kutlay S, Ozen S, Erturk S, Oner A et al (2003) Analysis of the modifying effects of SAA1, SAA2 and TNF-alpha gene polymorphisms on development of amyloidosis in FMF patients. Turk J Pediatr 45:198-202
88. Saatci U, Ozen S, Ozdemir S, Bakkaloglu A, Besbas N, Topaloglu R et al (1997) Familial Mediterranean fever in children: report of a large series and discussion of the risk and prognostic factors of amyloidosis. Eur J Pediatr 156:619-623
89. Schwabe AD, Peters RS (1974) Familial Mediterranean fever in Armenians. Analysis of 100 cases. Medicine (Baltimore) 53:453-462
90. Lidar M, Scherrmann JM, Shinar Y, Chetrit A, Niel E, Gershoni-Baruch R et al (2004) Colchicine nonresponsiveness in familial Mediterranean fever: clinical, genetic, pharmacokinetic, and socioeconomic characterization. Semin Arthritis Rheum 33:273-282
91. Zemer D, Pras M, Sohar E, Modan M, Cabili S, Gafni J (1986) Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med 314:1001-1005
92. Vigneau C, Petrover D, Sraer JD (2001) Late occurrence of chronic renal failure in familial Mediterranean fever after 20 years of colchicine treatment. Ann Intern Med 135:1096
93. Zemer D, Livneh A, Langevitz P (1992) Reversal of the nephrotic syndrome by colchicine in amyloidosis of familial Mediterranean fever. Ann Intern Med 116:426
94. Oner A, Erdogan O, Demircin G, Bulbul M, Memis L (2003) Efficacy of colchicine therapy in amyloid nephropathy of familial Mediterranean fever. Pediatr Nephrol 18:521-526
95. Cakar N, Yalcinkaya F, Ozkaya N, Tekin M, Akar N, Kocak H et al (2001) Familial Mediterranean fever (FMF)-associated amyloidosis in childhood. Clinical features, course and outcome. Clin Exp Rheumatol 19:S63-S67
96. Altiparmak MR, Pamuk ON, Ataman R, Serdengecti K (2004) Continuous ambulatory peritoneal dialysis in familial Mediterranean fever amyloidosis patients with end-stage renal failure: a single-centre experience from Turkey. Nephron Clin Pract 98:c119-c123
97. Ari JB, Zlotnik M, Oren A, Berlyne GM (1976) Dialysis in renal failure caused by amyloidosis of familial Mediterranean fever. A report of ten cases. Arch Intern Med 136:449-451
98. Sherif AM, Refaie AF, Sobh MA, Mohamed NA, Sheashaa HA, Ghoneim MA (2003) Long-term outcome of live donor kidney transplantation for renal amyloidosis. Am J Kidney Dis 42:370-375
99. Jacob ET, Bar-Nathan N, Shapira Z, Gafni J (1979) Renal transplantation in the amyloidosis of familial Mediterranean fever. Experience in ten cases. Arch Intern Med 139:1135-1138
100. Livneh A, Zemer D, Siegal B, Laor A, Sohar E, Pras M (1992) Colchicine prevents kidney transplant amyloidosis in familial Mediterranean fever. Nephron 60:418-422
101. Keven K, Sengul S, Kutlay S, Ekmekci Y, Anadol E, Nergizoglu G et al (2004) Long-term outcome of renal transplantation in patients with familial Mediterranean fever amyloidosis: a single-center experience. Transplant Proc 36:2632-2634
102. Zemer D, Livneh A, Pras M, Sohar E (1993) Familial Mediterranean fever in the colchicine era: the fate of one family. Am J Med Genet 45:340-344
103. Duzova A, Bakkaloglu A, Besbas N, Topaloglu R, Ozen S, Ozaltin F et al (2003) Role of A-SAA in monitoring subclinical inflammation and in colchicine dosage in familial Mediterranean fever. Clin Exp Rheumatol 21:509-514
104. Williamson LM, Hull D, Mehta R, Reeves WG, Robinson BH, Toghill PJ (1982) Familial Hibernian fever. Q J Med 51:469-480
105. Galon J, Aksentijevich I, McDermott MF, O'Shea JJ, Kastner DL (2000) TNF receptor-associated periodic syndromes (TRAPS): mutations in TNFR1 and early experience with Etanercept therapy. FASEB J 14:A1150
106. Simon A, Dode C, van der Meer JWM, Drenth JPH (2001) Familial periodic fever and amyloidosis due to a new mutation in the TNFRSF1A gene. Am J Med 110:313-316
107. Aksentijevich I, Galon J, Soares M, Mansfield E, Hull K, Oh HH et al (2001) The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers. Am J Hum Genet 69:301-314
108. McDermott MF, Aksentijevich I, Galon J, McDermott EM, Ogunkolade BW, Centola M et al (1999) Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 97:133-144
109. Dode C, Andre M, Bienvenu T, Hausfater P, Pecheux C, Bienvenu J et al (2002) The enlarging clinical, genetic, and population spectrum of tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 46:2181-2188
110. Chen G, Goeddel DV (2002) TNF-R1 signaling: a beautiful pathway. Science 296:1634-1635
111. McDermott EM, Smillie DM, Powell RJ (1997) Clinical spectrum of familial Hibernian fever: a 14-year follow-up study of the index case and extended family. Mayo Clin Proc 72:806-817
112. Hull KM, Drewe E, Aksentijevich I, Singh HK, Wong K, McDermott EM et al (2002) The TNF receptor-associate periodic syndrome (TRAPS) - emerging concepts of an autoinflammatory disorder. Medicine 81:349-368
113. Toro JR, Aksentijevich I, Hull K, Dean J, Kastner DL (2000) Tumor necrosis factor receptor-associated periodic syndrome: a novel syndrome with cutaneous manifestations. Arch Dermatol 136:1487-1494
114. Bodar EJ, Simon A, van der Hilst JC, van Deuren M (2004) Two patients with recurrent fever and wine red discolouration of the eyelids. Neth J Med 62:119-120, 139
115. Aksentijevich I, Nowak M, Mallah M, Chae JJ, Watford WT, Hofmann SR et al (2002) De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum 46:3340-3348
116. Kallinich T, Briese S, Roesler J, Rudolph B, Sarioglu N, Blankenstein O et al (2004) Two familial cases with tumor necrosis factor receptor-associated periodic syndrome caused by a non-cysteine mutation (T50M) in the TNFRSF1A gene associated with severe multiorganic amyloidosis. J Rheumatol 31:2519-2522
117. Jadoul M, Dode C, Cosyns JP, Abramowicz D, Georges B, Delpech M et al (2001) Autosomal-dominant periodic fever with AA amyloidosis: novel mutation in tumor necrosis factor receptor 1 gene. Rapid Communication. Kidney Int 59:1677-1682
118. Drewe E, McDermott EM, Powell PT, Isaacs JD, Powell RJ (2003) Prospective study of anti-tumour necrosis factor receptor superfamily 1B fusion protein, and case study of anti-tumour necrosis factor receptor superfamily 1A fusion protein, in tumour necrosis factor receptor associated periodic syndrome (TRAPS): clinical and laboratory findings in a series of seven patients. Rheumatology (Oxford) 42:235-239
119. Heller A, Trifonov V, Rubtsov N, Sauerbrey A, Starke H, Loncarevic IF et al (2003) Complex chromosomal rearrangements in a secondary acute myeloblastic leukemia after chemotherapy in TRAPS. Oncol Rep 10:1789-1792
120. Drewe E, Huggins ML, Morgan AG, Cassidy MJ, Powell RJ (2004) Treatment of renal amyloidosis with etanercept in tumour necrosis factor receptor-associated periodic syndrome. Rheumatology (Oxford) 43:1405-1408
121. Drewe E, McDermott EM, Powell RJ (2000) Treatment of the nephrotic syndrome with etanercept in patients with the tumor necrosis factor receptor-associated periodic syndrome. N Engl J Med 343:1044-1045
122. Simon A, Bodar EJ, van der Hilst JC, van der Meer JW, Fiselier TJ, Cuppen MP et al (2004) Beneficial response to interleukin 1 receptor antagonist in traps. Am J Med 117:208-210
123. Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD (2001) Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 29:301-305
124. Feldmann J, Prieur AM, Quartier P, Berquin P, Certain S, Cortis E et al (2002) Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. Am J Hum Genet 71:198-203
125. Wang L, Manji GA, Grenier JM, Al Garawi A, Merriam S, Lora JM et al (2002) PYPAF7, a novel PYRIN-containing Apaf1-like protein that regulates activation of NF-kappa B and caspase-1-dependent cytokine processing. J Biol Chem 277:29874-29880
126. Manji GA, Wang L, Geddes BJ, Brown M, Merriam S, Al Garawi A et al (2002) PYPAF1, a PYRIN-containing Apaf1-like protein that assembles with ASC and regulates activation of NF-kappa B. J Biol Chem 277:11570-11575
127. Dode C, Le Du N, Cuisset L, Letourneur F, Berthelot JM, Vaudour G et al (2002) New mutations of CIAS1 that are responsible for Muckle-Wells syndrome and familial cold urticaria: a novel mutation underlies both syndromes. Am J Hum Genet 70:1498-1506
128. Doeglas HM, Bleumink E (1974) Familial cold urticaria. Clinical findings. Arch Dermatol 110:382-388
129. Hoffman HM, Wanderer AA, Broide DH (2001) Familial cold autoinflammatory syndrome: phenotype and genotype of an autosomal dominant periodic fever. J Allergy Clin Immunol 108:615-620
130. Muckle TJ (1979) The 'Muckle-Wells' syndrome. Br J Dermatol 100:87-92
131. Hawkins PN, Lachmann HJ, Aganna E, McDermott MF (2004) Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum 50:607-612
132. Haas N, Kuster W, Zuberbier T, Henz BM (2004) Muckle-Wells syndrome: clinical and histological skin findings compatible with cold air urticaria in a large kindred. Br J Dermatol 151:99-104
133. Prieur AM, Griscelli C, Lampert F, Truckenbrodt H, Guggenheim MA, Lovell DJ et al (1987) A chronic, infantile, neurological, cutaneous and articular (CINCA) syndrome. A specific entity analysed in 30 patients. Scand J Rheumatol Suppl 66:57-68
134. Hentgen V, Despert V, Lepretre AC, Cuisset L, Chevrant-Breton J, Jego P et al (2005) Intrafamilial variable phenotypic expression of a CIAS1 mutation: from Muckle-Wells to chronic infantile neurological cutaneous and articular syndrome. J Rheumatol 32:747-751
135. Granel B, Philip N, Serratrice J, Ene N, Grateau G, Dode C et al (2003) CIAS1 mutation in a patient with overlap between Muckle-Wells and chronic infantile neurological cutaneous and articular syndromes. Dermatology 206:257-259
136. Muckle TJ, Wells M (1962) Urticaria, deafness, and amyloidosis: a new heredo-familial syndrome. Q J Med 31:235-248
137. Aganna E, Hammond L, Hawkins PN, Aldea A, McKee SA, van Amstel HK et al (2003) Heterogeneity among patients with tumor necrosis factor receptor-associated periodic syndrome phenotypes. Arthritis Rheum 48:2632-2644
138. Fuger K, Fleischmann E, Weber M, Mann J (1992) [Complications in the course of the Muckle-Wells syndrome]. Dtsch Med Wochenschr 117:256-260
139. Bustorff MM, Oliveria JP, Moura C, Carvalho E, Faria V, Guerra L (1995) Muckle-Wells syndrome nephropathy: lack of response to colchicine therapy. Nephrol Dial Transplant 10:709-710
140. Hoffman HM, Rosengren S, Boyle DL, Cho JY, Nayar J, Mueller JL et al (2004) Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 364:1779-1785
141. Aganna E, Hawkins PN, Ozen S, Pettersson T, Bybee A, McKee SA et al (2004) Allelic variants in genes associated with hereditary periodic fever syndromes as susceptibility factors for reactive systemic AA amyloidosis. Genes Immun 5:289-293
142. Granel B, Serratrice J, Disdier P, Weiller PJ (2005) Dramatic improvement with anakinra in a case of chronic infantile neurological cutaneous and articular (CINCA) syndrome. Rheumatology (Oxford).
143. van der Meer JWM, Vossen JM, Radl J, van Nieuwkoop JA, Meyer CJ, Lobatto S et al (1984) Hyperimmunoglobulinaemia D and periodic fever: a new syndrome. Lancet 1:1087-1090
144. Drenth JPH, Cuisset L, Grateau G, Vasseur C, van de Velde-Visser SD, de Jong JG et al (1999) Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome. International Hyper-IgD Study Group. Nat Genet 22:178-181
145. Houten SM, Kuis W, Duran M, de Koning TJ, Royen-Kerkhof A, Romeijn GJ et al (1999) Mutations in MVK, encoding mevalonate kinase, cause hyperimmunoglobulinaemia D and periodic fever syndrome. Nat Genet 22:175-177
146. Houten SM, Wanders RJ, Waterham HR (2000) Biochemical and genetic aspects of mevalonate kinase and its deficiency. Biochim Biophys Acta 1529:19-32
147. Drenth JP, van der Meer JW, Kushner I (1996) Unstimulated peripheral blood mononuclear cells from patients with the hyper-IgD syndrome produce cytokines capable of potent induction of C-reactive protein and serum amyloid A in Hep3B cells. J Immunol 157:400-404
148. Drenth JP, Goertz J, Daha MR, van der Meer JW (1996) Immunoglobulin D enhances the release of tumor necrosis factor-alpha, and interleukin-1 beta as well as interleukin-1 receptor antagonist from human mononuclear cells. Immunology 88:355-362
149. Frenkel J, Rijkers GT, Mandey SH, Buurman SW, Houten SM, Wanders RJ et al (2002) Lack of isoprenoid products raises ex vivo interleukin-1 beta secretion in hyperimmunoglobulinemia D and periodic fever syndrome. Arthritis Rheum 46:2794-2803
150. Drenth JP, Haagsma CJ, van der Meer JW (1994) Hyperimmunoglobulinemia D and periodic fever syndrome. The clinical spectrum in a series of 50 patients. International Hyper-IgD Study Group. Medicine (Baltimore) 73:133-144
151. van der Hilst JC, Simon A, Drenth JP (2003) Molecular mechanisms of amyloidosis. N Engl J Med 349:1872-1873
152. Obici L, Manno C, Muda AO, Picco P, D'Osualdo A, Palladini G et al (2004) First report of systemic reactive (AA) amyloidosis in a patient with the hyperimmunoglobulinemia D with periodic fever syndrome. Arthritis Rheum 50:2966-2969
153. van der Hilst JCH, Drenth JP, Bodar EJ, van der Meer JWM, Simon A (2005) Serum amyloid A serum concentrations and genotype do not explain low incidence of amyloidosis in Hyper-IgD syndrome. Amyloid 12:115-119
154. Drenth JP, Vonk AG, Simon A, Powell R, van der Meer JW (2001) Limited efficacy of thalidomide in the treatment of febrile attacks of the hyper-IgD and periodic fever syndrome: a randomized, double-blind, placebo-controlled trial. J Pharmacol Exp Ther 298:1221-1226
155. Simon A, Drewe E, van der Meer JW, Powell RJ, Kelley RI, Stalenhoef AF et al (2004) Simvastatin treatment for inflammatory attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Clin Pharmacol Ther 75:476-483
156. Simon A, Bijzet J, Voorbij HA, Mantovani A, van der Meer JW, Drenth JP (2004) Effect of inflammatory attacks in the classical type hyper-IgD syndrome on immunoglobulin D, cholesterol and parameters of the acute phase response. J Intern Med 256:247-253
157. Takada K, Aksentijevich I, Mahadevan V, Dean JA, Kelley RI, Kastner DL (2003) Favorable preliminary experience with etanercept in two patients with the hyperimmunoglobulinemia D and periodic fever syndrome. Arthritis Rheum 48:2645-2651
158. Arkwright PD, McDermottt MF, Houten SM, Frenkel J, Waterhan HR, Aganna E et al (2002) Hyper IgD syndrome (HIDS) associated with in vitro evidence of defective monocyte TNFRSF1A shedding and partial response to TNF receptor blockade with etanercept. Clin Exp Immunol 130:484-488
159. Marchetti F, Barbi E, Tommasini A, Oretti C, Ventura A (2004) Inefficacy of etanercept in a child with hyper-IgD syndrome and periodic fever. Clin Exp Rheumatol 22:791-792
160. Bodar EJ, van der Hilst JC, Drenth JP, van der Meer JWM, Simon A (2005) Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: introducing a vaccination provocation model. Neth J Med 63:260-264
161. Drenth JPH, Der Meer JW (2000) Periodic fevers enter the era of molecular diagnosis. BMJ 320:1091-1092
162. Eliakim M (1970) Incidence of amyloidosis in recurrent polyserositis (familial Mediterranean fever). Isr J Med Sci 6:2-8
163. Ozdemir AI, Sokmen C (1969) Familial Mediterranean fever among the Turkish people. Am J Gastroenterol 51:311-316
164. Sayarlioglu M, Cefle A, Inanc M, Kamali S, Dalkilic E, Gul A et al (2005) Characteristics of patients with adult-onset familial Mediterranean fever in Turkey: analysis of 401 cases. Int J Clin Pract 59:202-205
165. Majeed HA, Barakat M (1989) Familial Mediterranean fever (recurrent hereditary polyserositis) in children: analysis of 88 cases. Eur J Pediatr 148:636-641
166. Zaks N, Shinar Y, Padeh S, Lidar M, Mor A, Tokov I et al (2003) Analysis of the three most common MEFV mutations in 412 patients with familial Mediterranean fever. Isr Med Assoc J 5:585-588
167. Dode C, Pecheux C, Cazeneuve C, Cattan D, Dervichian M, Goossens M et al (2000) Mutations in the MEFV gene in a large series of patients with a clinical diagnosis of familial Mediterranean fever. Am J Med Genet 92:241-246